FindTrial
Sign In

Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphoma

Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN26863825
Enrollment
Unknown
Registered
2002-08-19
Start date
1995-01-01
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkin's) Cancer Lymphoma (non-Hodgkin's)

Interventions

Patients are randomised to one of two treatment regimens: 1. CHOP Regimen: Adriamycin, cyclophosphamide, vincristine and prednisone cycle repeated every 3 weeks. Chemotherapy to be giv

Sponsors

British National Lymphoma Investigation (BNLI) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 16-59 years 2. No medical conditions, other than lymphoma, prohibiting intensive therapy and no systemic treatment for cancer in previous 5 years 3. One of the following histological types: 3.1 Follicular large cell 3.2 Diffuse mixed cell 3.3 Diffuse large cell 3.4 Diffuse immunoblastic lymphomas 4. Full clinical staging to include Computed Tomography (CT) scanning of abdomen and bone marrow trephine biopsy 5. Good prognostic features defined as the presence of less than two of: 5.1 Stage III/IV 5.2 Lactic dehydrogenase (LDH) >normal 5.3 Eastern Cooperative Oncology Group (ECOG) or World Health Organisation (WHO) performance status 2-4

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026